REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive lymphoma: drug combo aims to unmask cancer cells
Disease control OngoingThis study tests a combination of two drugs (TTI-622 and pembrolizumab) in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. The drugs work by helping the immune system recognize and attack cancer cells. The goal is to find …
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
Experimental combo aims to supercharge immune cells against Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests whether adding an experimental drug (NKTR-255) to standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has returned or not responded to treatment. About 27 participants will receive the combination to see if it i…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:54 UTC
-
New Triple-Drug attack shows promise against tough lymphomas
Disease control OngoingThis study tests a new drug combination (ALX148, rituximab, and lenalidomide) in people with slow-growing or fast-growing B-cell non-Hodgkin lymphoma that has not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink or eliminate tumors. …
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC